{{Rsnum
|rsid=7900929
|Chromosome=10
|position=126584999
|Orientation=plus
|GMAF=0.1745
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 69.0 | 29.2 | 1.8
| HCB | 65.0 | 32.1 | 2.9
| JPT | 57.5 | 37.2 | 5.3
| YRI | 61.2 | 33.3 | 5.4
| ASW | 68.4 | 29.8 | 1.8
| CHB | 65.0 | 32.1 | 2.9
| CHD | 70.6 | 24.8 | 4.6
| GIH | 70.3 | 23.8 | 5.9
| LWK | 66.4 | 30.9 | 2.7
| MEX | 62.1 | 32.8 | 5.2
| MKK | 53.2 | 41.0 | 5.8
| TSI | 75.5 | 22.5 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7900929
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.15, combined P value= 1.23E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470191
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7900929
|overall_frequency_n=22
|overall_frequency_d=128
|overall_frequency=0.171875
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=22
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}